{Reference Type}: Journal Article
{Title}: Metagenomic next-generation sequencing testing from the perspective of clinical benefits.
{Author}: Chen M;Cai Y;Wang L;Jiang Y;Qian J;Qin J;Xu J;Li J;Yu S;Shen B;
{Journal}: Clin Chim Acta
{Volume}: 553
{Issue}: 0
{Year}: 2024 Jan 15
{Factor}: 6.314
{DOI}: 10.1016/j.cca.2023.117730
{Abstract}: <B>OBJECTIVE: </B>Metagenomic next-generation sequencing (mNGS) provided promising supports to rapid pathogen diagnosis. However, summary of scientific application strategy based on clinical practice study is still necessary for enhancing clinical benefits.<BR><B>METHODS: </B>We conducted a retrospective analysis of 775 samples from patients with suspected infectious diseases (IDs). Based on final diagnosis, diagnostic performance, clinical relevance and clinical impact of mNGS among various clinical settings were assessed, and influencing factors were deeply explored.<BR><B>RESULTS: </B>84.26 % tests were clinically relevant; sample, but not sequencing, was the influencing factor. 40.77 % tests contributed to positive clinical impact, while 0.13 % and 59.10 % to negative and no impact respectively. mNGS utility in patients with IDs, definite infection site, BALF and CSF contributed to higher positive impacts. Days of empirical treatment before sampling ≤ 5 in ICU and ≤ 2 or between 11 and 20 in non-ICU, and reporting in 2 days brought about higher clinical benefit rates. Characteristic pathogen spectrum between ICU and non-ICU cases were revealed.<BR><B>CONCLUSIONS: </B>Our findings highlighted clinical benefits from mNGS varied among different clinical settings, and elucidated choices on patients, samples, sampling and reporting time were four key factors. Rational strategy should be concerned to promote scientific application of mNGS and better improve clinical value.